menu

Investigating SGLT-2 Inhibitors in Diabetes: Considerations & Conversation

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Investigating SGLT-2 Inhibitors in Diabetes: Considerations & Conversation

ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    SGLT-2 inhibitors have been authorized for diabetic patients in Europe, but is it close to receiving FDA approval in the U.S.? Dr. Anne Peters of USC speaks with Dr. John Buse about SGLT-2 inhibitors and considerations for diabetic ketoacidosis, heart failure, and chronic kidney disease.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    SGLT-2 inhibitors have been authorized for diabetic patients in Europe, but is it close to receiving FDA approval in the U.S.? Dr. Anne Peters of USC speaks with Dr. John Buse about SGLT-2 inhibitors and considerations for diabetic ketoacidosis, heart failure, and chronic kidney disease.

Facebook Comments

Schedule1 Oct 2022
Webpack App